Develops a novel and safe treatment for acute ischemic stroke.
Acticor Biotech is a biopharmaceutical company, founded in 2013 as a spin-off of Inserm (Paris, France), developing an innovative drug for the treatment in the acute phase of ischemic stroke.
According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 6 million die and another 5 million are permanently disabled.
Acticor is developing ACT-017, a humanized Antibody Fragment (Fab). The therapeutic candidate is directed against a novel target of major interest, platelet glycoprotein VI (GPVI), and inhibits its action. Evidence of antithrombotic efficacy of ACT-017 and safety of inhibition of GPVI have been established both ex vivo and in vivo. The target is involved in the growth of the thrombus, but not in physiological hemostasis. This limits the bleeding risk associated with its inhibition.